Shots:
- The P-III (BRUIN CLL-314) trial assessed Jaypirca vs Imbruvica in 650 pts with treatment-naïve or experienced (but BTK-naïve) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
- Trial met its 1EP of ORR non-inferiority in both pre-treated & ITT pts, with ORR favoring Jaypirca; PFS was immature but showed favorable trend, especially in treatment-naïve pts (n=225) who had the longest follow-up; no OS detriment was observed. PFS analysis is planned in future, with detailed results to be shared in 2025
- Additionally, the P-III (BRUIN CLL-313) trial evaluating Jaypirca vs chemoimmunotherapy in treatment-naïve CLL/SLL pts is expected to report results in late 2025 &, along with BRUIN CLL-314 data, will support global regulatory filings
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News:- Eli Lilly Receives the Health Canada’s Approval for Omvoh (Mirikizumab) to Treat Crohn’s Disease (CD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
